Stocktoria
BIOVIE INC. BIVI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-01-14
BIOVIE INC. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $14.0M | $9.3M | $23.1M | $33.3M | $17.3M | $2.5M | $1.2M | $1.0M | $370,852 | $466,354 |
| SG&A expense | — | $8.6M | $8.8M | $11.6M | $9.8M | $4.6M | $1.3M | $1.3M | $1.8M | $69,122 |
| Operating income | -$22.7M | -$18.1M | -$32.2M | -$45.1M | -$27.3M | -$138.1M | -$2.7M | -$2.5M | -$2.4M | -$1.6M |
| Interest expense | $17,901 | $332,720 | $2.9M | $4.3M | $2.2M | $559,455 | $4.8M | $273 | $40,960 | — |
| Net income | -$22.1M | -$17.5M | -$32.1M | -$50.3M | -$26.1M | -$130.2M | -$16.7M | — | -$2.4M | -$1.3M |
| EPS (diluted) | $-3.05 | $-12.12 | $-73.05 | $-15.47 | $-1.06 | $-14.82 | $-6.85 | $-0.98 | — | — |
| Operating cash flow | -$19.0M | -$19.0M | -$27.9M | -$40.3M | -$19.0M | -$10.5M | -$1.6M | -$2.5M | -$621,341 | -$623,615 |
| Cash & equivalents | $9.0M | $17.5M | $23.8M | $19.5M | $18.6M | — | — | — | — | — |
| Total assets | $14.3M | $21.6M | $25.2M | $35.1M | $20.1M | $6.0M | $2.1M | $2.6M | $2.2M | $2.4M |
| Total liabilities | $4.0M | $2.6M | $9.7M | $19.8M | $16.4M | $996,374 | $23.6M | $443,480 | $2.1M | $1.2M |
| Shareholders' equity | $10.3M | $19.0M | $15.5M | $15.3M | $3.7M | $5.1M | -$21.5M | $2.1M | $111,199 | $1.2M |
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.